Diagnostic utility of lipocalin 2 and metalloproteinase 9 levels in early-stage endometrial cancer

Basit Öğe Kaydı
dc.contributor.authorUnuvar, Songul
dc.contributor.authorMelekoglu, Rauf
dc.contributor.authorYuce, Hande
dc.contributor.authorCelik, Nesibe Zeyveli
dc.contributor.authorOkumus, Ezgi Bulut
dc.contributor.authorToprak, Serhat
dc.contributor.authorTanbek, Kevser
dc.date.accessioned2026-04-04T13:33:13Z
dc.date.available2026-04-04T13:33:13Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground Endometrial cancer (EC) is the fourth most common gynecologic malignancy among women. Histopathologic examination is considered gold-standard for diagnosis of EC. However, these examinations sometimes not be useful in distinguishing early stage types of EC. Object & imath;ves The current study aimed to investigate the clinicopathological significance of Lipocalin-2 (LCN2), matrix metalloproteinase-9 (MMP9), and ferritin in tumor progression. Methods A total of 98 patients (55 women newly diagnosed with early-stage endometrial cancer [study group] and 43 women with benign endometrial pathologies [control group]) were enrolled. Results There was a significant difference between diagnosis (p < 0.001), surgical procedure (p < 0.001), pathology (p = 0.002), stage (p < 0.001), lymphovascular invasion (LVI) (p = 0.002), myometrial invasion (p < 0.001), and staining intensity (p < 0.001), MMP9 (p = 0.023), LCN2 (p < 0.001), glucocorticoid (GC) (p = 0.048), tumor necrosis factor-alpha (TNF-alpha) (p = 0.044), menopause duration (p = 0.001), body weight (p < 0.001), and body mass index (BMI) (p < 0.001) were found to be higher, and ferritin levels (p = 0.047) were lower in the endometrial adenocarcinoma group compared to the benign endometrial pathologies. Conclus & imath;on LCN2, MMP9, and ferritin are practical markers in early cases of endometrial cancer. Serum LCN2 and MMP9 levels may be good clinical tools for the auxiliary diagnosis of early-stage endometrial cancer. Ferritin was also significantly sensitive. Therefore, detecting these markers together may be more beneficial for cancer diagnosis.
dc.description.sponsorshipInonu University Department of Scientific Research Projects [TSA-2022/2776]
dc.description.sponsorshipThis study was supported by the Inonu University Department of Scientific Research Projects (Project number: TSA-2022/2776).
dc.identifier.doi10.1177/18758592241290951
dc.identifier.issn1574-0153
dc.identifier.issn1875-8592
dc.identifier.issue3-4
dc.identifier.orcid0000-0001-8454-490X
dc.identifier.orcid0000-0001-7113-6691
dc.identifier.orcid0000-0003-4136-0523
dc.identifier.orcid0000-0003-4160-2270
dc.identifier.pmid39973816
dc.identifier.scopus2-s2.0-85219133752
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1177/18758592241290951
dc.identifier.urihttps://hdl.handle.net/11616/109000
dc.identifier.volume41
dc.identifier.wosWOS:001481853300001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofCancer Biomarkers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectEndometrial cancer
dc.subjectlipocalin
dc.subjectbiomarker
dc.subjectMMP9
dc.subjectTIMP1
dc.subjectferritin
dc.titleDiagnostic utility of lipocalin 2 and metalloproteinase 9 levels in early-stage endometrial cancer
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu